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Abstract
Background: Growth factors induce a characteristically short-lived Ras activation in cells emerging from
quiescence. Extensive work has shown that transient as opposed to sustained Ras activation is critical for the
induction of mitogenic programs. Mitogen-induced accumulation of active Ras-GTP results from increased
nucleotide exchange driven by the nucleotide exchange factor Sos. In contrast, the mechanism accounting
for signal termination and prompt restoration of basal Ras-GTP levels is unclear, but has been inferred to
involve feedback inhibition of Sos. Remarkably, how GTP-hydrolase activating proteins (GAPs) participate in
controlling the rise and fall of Ras-GTP levels is unknown.
Results: Monitoring nucleotide exchange of Ras in permeabilized cells we find, unexpectedly, that the decline
of growth factor-induced Ras-GTP levels proceeds in the presence of unabated high nucleotide exchange, pointing to
GAP activation as a major mechanism of signal termination. Experiments with non-hydrolysable GTP analogues and
mathematical modeling confirmed and rationalized the presence of high GAP activity as Ras-GTP levels decline in a
background of high nucleotide exchange. Using pharmacological and genetic approaches we document a raised
activity of the neurofibromatosis type I tumor suppressor Ras-GAP neurofibromin and an involvement of Rsk1 and Rsk2
in the down-regulation of Ras-GTP levels.
Conclusions: Our findings show that, in addition to feedback inhibition of Sos, feedback stimulation of the RasGAP
neurofibromin enforces termination of the Ras signal in the context of growth-factor signaling. These findings ascribe
a precise role to neurofibromin in growth factor-dependent control of Ras activity and illustrate how, by engaging
Ras-GAP activity, mitogen-challenged cells play safe to ensure a timely termination of the Ras signal irrespectively of
the reigning rate of nucleotide exchange.
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Plain English summary
Ras activation in response to growth factor stimulation
is a central mitogenic signaling pathway. Extensive work
has shown that the duration of the Ras signal is a key
determinant of cell fate in the sense that growth factor
activation of Ras must be transient to promote a proper
proliferative response. It is well established that growth
factors stimulate the nucleotide exchange factor (GEF)
Sos to promote Ras activation via Ras-GTP loading but
it is not known how Ras activation is terminated to en-
sure a short-lived signal. We document here a new
mechanism for Ras signal termination, namely activation
of a RasGAP activity in the context of a feedback signal
propagated via Rsk1 and Rsk2, the kinase mutated in
Coffin-Lowry syndrome. We provide evidence that neu-
rofibromin, the product of the tumor suppressor of
neurofibromatosis type 1 (NF1), is the RasGAP species
mediating the deactivation of Ras. In summary our find-
ings disclose a positive feedback loop leading to the
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stimulation of neurofibromin as a mechanism that
restricts the duration of growth factor-induced Ras
activation.
Background
Cells emerging from quiescence upon growth factor en-
counter feature a pronounced activation of Ras which is
characteristically short-lived. Extensive work has eluci-
dated that the duration of the signal elicited by Ras is
decisive for cell fate decision taking. For example, sem-
inal studies in PC12 phaechromocytoma cells illustrate
that the duration of the signal provided by Ras and its
downstream effector kinase Erk is the key event deter-
mining whether these cells will enter the cell cycle or
cease proliferation and differentiate in response to a
given stimulus [1–6]. Accordingly, the mechanisms
mediating agonist control of Ras-GDP/GTP levels have
been the focus of intense research.
Accumulation of active Ras-GTP in response to
growth factors is understood in some detail. It results
from the stimulation of the ubiquitous guanine nucleo-
tide exchange factor (GEF) Sos and the consequent pro-
motion of nucleotide exchange on Ras [7–10]. Less is
known, however, about the reactions accounting for the
equally fast reversal of Ras-GTP levels, a process we
refer to as Ras deactivation. Current models invoke
feedback inhibition of Sos as a critical step [11–14],
based on the observation that Sos gets phosphorylated
downstream of the Ras effector kinases MEK [15] and/
or Erk [13, 16–18]. Erk phosphorylates multiple sites at
the Sos C-terminus, promoting the dissociation of Sos
from the adapter protein Grb-2 [16–19]. This reaction is
inferred to down-modulate Sos activity by removing Sos
from the vicinity of Ras, although not all studies are in
support of this model [19–22].
Acting downstream of Erk, the two p90 ribosomal S6
kinase (Rsk) family members Rsk1 and Rsk2 have been
identified as additional Sos kinases. Rsk2 phosphorylates
Sos in vitro [23] and both Rsk1 and Rsk 2 reportedly
phosphorylate Sos in vivo on two sites conforming to
the minimal Rsk consensus motif [24]. Sos phosphoryl-
ation by Rsk creates docking sites for 14-3-3 proteins,
and it is proposed that Sos/14-3-3 complex formation si-
lences Sos activity [24]. Consistent with this model, pre-
venting Sos phosphorylation by Rsk enhanced Erk
activity but the effect was modest if compared to the
consequences of MEK blockade, suggesting that modula-
tion of Sos activity by Rsk1/2 is one out of many mecha-
nisms accounting for the termination of Ras signaling. A
role of Rsk1/2 in feedback control of Ras-GTP levels is
further supported by studies illustrating that Rsk inhib-
ition elevates the levels of activated Erk both at steady
state or basal conditions [25–29] or in response to growth
factor stimulation [24, 25, 30, 31]. Taken together these
reports provide strong evidence for a feedback regulation
of Ras-GTP levels mediated by Erk and/or Rsk1/2 impin-
ging on Sos. However, it is worth to note that although
Sos phosphorylation by Erk or Rsk1/2 is inferred to down-
regulate Sos activity this link has not rigorously been
proved since the nucleotide exchange activity of Sos was
not analyzed in the referred studies.
While the role of Sos in Ras activation/deactivation
has been intensively studied, the involvement of GTP-
hydrolase activating proteins (GAPs) and in particular
any mitogen-induced changes in GAP activity is less well
explored. This lack of insight is owed not least to the
fact that it is technically challenging to monitor GAP
activity in life cells. Among the various human GAP
families, neurofibromin, the product of the tumor sup-
pressor gene NF1 has attracted particular attention given
its frequent loss in human cancer [32, 33], which is
strong circumstantial evidence for a function of neurofi-
bromin in the control of mitogenic Ras signaling. As
regards the precise role of neurofibromin, a recent series
of studies has documented transient ubiquitination and
proteasomal degradation of neurofibromin as a process
contributing to the growth factor-induced accumulation
of Ras-GTP [34–36]. The growth factor-triggered loss of
neurofibromin protein was short-lived and related in-
versely with Ras-GTP levels, pointing to the short-term
control of neurofibromin levels as one regulatory mechan-
ism of Ras activation and deactivation. However, this
mechanism may be restricted to certain cell types, since a
growth-factor elicited drop of neurofibromin levels was
not observed in other systems [37–40]. Thus, despite the
strong interest in understanding neurofibromin function,
the precise role played by neurofibromin in growth-factor
control of Ras activity, if any, is still unclear.
In summary, the concept of feedback inhibition of Sos
as the dominant mechanism of Ras deactivation has pre-
vailed, perhaps due in part to the penury of data on Ras-
GAP function in growth factor signaling. The need to
advance in our understanding of Ras-GAP regulation is
reinforced by mathematical simulations which predicted
that Sos downregulation is insufficient to effectively de-
activate Ras without invoking high GAP activity [41, 42].
Thus, while there is strong evidence pointing to a role
for feedback inhibition of Sos in Ras deactivation, the
full mechanism accounting for the transient nature of
Ras activation is far from being understood. We have
undertaken this study to elucidate the role of GEFs and
GAPs during the process of Ras deactivation.
Results and discussion
EGF induces transient Ras activation and feedback
phosphorylation of Sos
Cells challenged with growth factors feature transient
Ras activation as shown here for EGF-stimulated HeLa
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(Fig. 1a) and MEF cells (Fig. 1b). Extensive work has put
forward feedback phosphorylation and concomitant
down-regulation of Sos activity downstream of the Ras/
Erk pathway as a step involved in signal termination
[11–14, 16–18, 23, 43]. In HeLa cells EGF induced a
shift in electrophoretic mobility of Sos (a commonly
used surrogate marker of Sos phosphorylation [11–14,
16–18, 23, 43]) that was fully abrogated by MEK or ERK
inhibition but was only partially affected by the Rsk
inhibitor BI-D1870 [26] or PI3K inhibition (Fig. 1c,
Additional file 1: Figure S1). This finding was consistent
with a negative feedback loop impinging on Sos down-
stream of Erk and possibly downstream of Rsk to initiate
Ras deactivation. Of note, in the present study we did
not consider effects of Ras-GEFs other than Sos given
the restricted neuronal and hematopoetic tissue distribu-
tion of the other two well-established Ras-GEF families,
RasGRP and RasGRF. In line with the reported pattern
of distribution, transcriptomic data sets confirmed the
absence of all RasGRP and RasGRF family members
from HeLa cells (GEO dataset ID GSE6783) [44].
High GAP activity is implicit to models of transient Ras
activation
While the role of Sos in Ras activation has been inten-
sively studied, the involvement of Ras-GAPs is less well
characterized. To understand the contribution of GAPs
we generated a minimal mathematical model describing
sequential growth factor-induced Sos activation, Ras-
GTP formation and a Ras-GTP-initiated feedback loop
of Sos-inhibition (Fig. 1d, Additional file 2: Table S1)
and simulated Ras activation/deactivation in the back-
ground of absent, low or high basal GAP activity
(Fig. 1e). In line with previous simulations [41], this ana-
lysis showed that models invoking feedback inhibition of
Sos require the implicit assumption of high basal GAP
activity in order to reproduce rapid Ras deactivation.
To investigate the role of Ras-GAPs we assessed first
their expression pattern. A proteomic study detected
RASA1, also known as p120GAP, and neurofibromin,
the product of the neurofibromatosis type 1 (NF1)
tumor suppressor in HeLa cells [45]. Transcriptome ana-
lysis also detected RASA1 and neurofibromin in HeLa
cells and no appreciable levels of RASA2, RASA3,
RASA4, RASAL1 or RASAL2 [44]. We confirmed the
predominant expression of RASA1 and neurofibromin
in HeLa cells (Fig. 1f ) and found also robust expression
of DAB2IP, a GAP described as tumor suppressor in
prostate cancer [46] (Fig. 1f ). To understand if Ras-
GAPs were active in resting HeLa cells, we investigated
the consequences of manipulating Ras-GAP levels. Re-
markably, single or combined knockdown of RASA1,
neurofibromin and DAB2IP resulted in a negligible
increase in Ras-GTP levels as compared to EGF
stimulation (Fig. 1f ), suggesting that GAPs were in a
dormant, inactive state in resting cells.
Growth factor induced Ras-GTP accumulation is transient
but the rise in Sos activity is sustained
The absence of high Ras-GAP activity was difficult to
reconcile with a model in which GAP action drives de-
activation of Ras following feedback inhibition of Sos,
unless Ras-GAPs became activated at later time points
of growth factor stimulation. To understand the contri-
bution of GAPs and GEFs we moved on to test these
predictions experimentally. The common Ras-activation
assay based on the affinity-precipitation of Ras-GTP
does not inform on GEF/GAP activities because it mea-
sures steady-state levels of Ras-GTP which reflect the
net result of GEF/GAP action. In order to monitor GEF
and/or GAP activity we adapted an approach to assess
nucleotide exchange on Ras at pre-steady-state in
permeabilized cells [7, 8, 47]. As seen in Fig. 2a pulsing
permeabilized HeLa cells with radiolabelled [α-32P]GTP
leads to the time-dependent incorporation of radioactiv-
ity into Ras-immunoprecipitates (IPs). Radioactivity was
specifically associated to Ras because it required the
input of the permeabilizing agent Streptolysin O (SLO)
and the Ras-IP antibody and was chased off by excess
GTP (Fig. 2a). Importantly, permeabilization did not
distort Ras activation kinetics although it did cause a
moderate attenuation of the Ras-GTP amplitude and
a progressive loss of Erk protein/activity beyond
10 min permeabilization time (Fig. 2b). It is import-
ant to note that all following permeabilization assays
in this study involved maximum permeabilization
times of 8 min or less.
To assess the role of Sos during rise and fall of Ras-
GTP levels we monitored nucleotide uptake by Ras at
discrete time points of EGF stimulation. EGF raised nu-
cleotide uptake by Ras at 5 min stimulation (the peak of
Ras-GTP accumulation) in HeLa (Fig. 2c) or MEF cells
(Fig. 2d), consistent with the notion that EGF engages
Sos to accelerate GTP-loading of Ras [7, 8, 47, 48]. Since
Ras deactivation is predicted to involve feedback-
inhibition of Sos we also measured nucleotide exchange at
15 or 20 min post-EGF, a time point at which Ras-GTP
levels have reverted in MEF and HeLa cells, respectively
(Fig. 1). Unexpectedly, we observed no reduction of
nucleotide exchange at 15/20 min EGF in either cell line
(Fig. 2c, d). To ascertain that Ras-GTP levels had truly
declined under these experimental conditions, nucleotides
associated to the same processed Ras-IPs were separated
by thin layer chromatography (Fig. 2c, d). This analysis
confirmed that Ras-GTP levels had strongly declined at
15/20 min EGF stimulation despite high nucleotide ex-
change in both cell types (Fig. 2e). Importantly, the associ-
ation of [α-32P]GTP to total protein did not change with
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Fig. 1 EGF induces transient Ras activation and Sos phosphorylation. a Transient Ras activation in HeLa cells. Serum-starved HeLa cells
were challenged with 10 ng/ml EGF and Ras activation was determined via Ras-GTP affinity pulldowns. EGFR and Erk phosphorylation
were determined using phosphosite-selective antibodies. A quantification of the Ras-GTP kinetics is shown on the right. RBD: Coomassie
stain of Ras binding domain used for collecting Ras-GTP. b MEF cells challenged with EGF were processed for Ras and Erk activity assays as in (a).
c EGF induces a mobility shift in Sos. HeLa cells were treated with inhibitors for MEK (10 μM U0126), Erk (50 μM FR108204) or Rsk (10 μM BI-D1870)
prior to stimulation with EGF. Extracts were processed via western blotting using the indicated antibodies. Asterisk marks an unspecific doublet band.
d Minimal Ras model describing Ras deactivation as induced by Ras-GTP-dependent feedback inhibition of Sos. R-GEF: receptor-GEF complex. See
experimental section for details. e Simulations of Ras activation/deactivation using the model from (d) in a background of absent, low or high basal
GAP activity. f Biochemical analysis of Ras-GTP levels following manipulation of Ras-GAP levels. The indicated Ras-GAP species were knocked down by
siRNA (siNF1, siRASA1, siDAB2IP) or transiently overexpressed in HeLa cells (GFP-NF1: GFP-neurofibromin fusion construct; HA-RASA1: HA-tagged RASA1;
asterisks mark overexpressed polypeptides). 5 min EGF stimulation is shown as positive control
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Fig. 2 EGF induces transient Ras-GTP accumulation but sustained up-regulation of nucleotide exchange. a Specificity of the Ras nucleotide exchange
assay in permeabilized cells. Serum-starved HeLa cells were permeabilized or mock permeabilized by omitting SLO in the presence of [α-32P]GTP.
A 100fold molar excess of unlabeled GTP was included where indicated. Cell extracts prepared at the indicated time points were subjected to Ras-IPs
or mock IPs lacking the Y13-259 Ras-antibody. Precipitates were washed and associated radioactivity evaluated by cerenkow counting. b Biochemical
assay of time-dependent EGF-induced Ras and Erk activation performed in the absence or presence of the permeabilizing agent SLO. SLO was added
simultaneously with EGF. c Nucleotide exchange assay in permeabilized HeLa cells before and 5 min or 20 min after EGF administration. Nucleotides
associated to Ras-IPs were additionally eluted from Ras and separated via thin layer chromatography (TLC, on the right). %GTP/(GDP + GTP) values
were determined by densitometry and plotted under the panel. Of note, initial values start off high and level off only at later time points. This pattern
is owed to the different time required for single Ras proteins versus the whole Ras population to achieve steady-state nucleotide turnover. d Same
experiment as in C performed in MEF cells. e Quantification of nucleotides bound to Ras-IPs. On the left, the amount of GDP + GTP bound to Ras at
the 6 min assay point (as recorded in (c)) was plotted as the fold increase of radioactivity bound to Ras in EGF-stimulated versus unstimulated cells.
On the right, the amount of GTP/(GDP + GTP) in the same assay points was plotted as % GTP/(GDP + GTP). Shown are means ± S.E.M.
for three independent experiments. f [α-32P]GTP associated to total cellular protein from untreated or EGF-challenged permeabilized cells determined
by a filter binding assay. Shown here is the means ± S.E.M. for three independent experiments. g GppNHp but not GTP promotes strong Ras activation
in permeabilized cells at late time points of EGF stimulation. HeLa cells were permeabilized for the indicated time frames in the presence of GTP or
GppNHp before (no stim.), 5 min or 20 min after EGF stimulation. Reactions were stopped by cell lysis and cell extracts were subjected to biochemical
analysis of Ras and Erk activation
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EGF stimulation (Fig. 2f), proving the specificity of the
assay. While these data argued against a major drop in Sos
activity during Ras deactivation, it should be noted that
the permeabilization-based nucleotide exchange assay
may not be sensitive enough to detect small and per-
haps locally confined changes in GEF activity. Thus,
although a contribution of Sos feedback inhibition
could not be excluded on the basis of these findings,
the simplest interpretation remained that Ras deacti-
vation involved the stimulation of a GAP activity at
late time points of EGF action.
To collect more evidence we combined the permea-
bilization assay with the Ras-GTP affinity pulldown. We
reasoned that Ras-GTP loading driven by the uptake of
the non-hydrolyzable GTP analogue GppNHp should
accurately mirror Sos activity, because Ras-GppNHp is
insensitive to GAP action. HeLa cells were permeabilized
in the presence of GTP or GppNHp before or after EGF
administration followed by the analysis of Ras activation
(Fig. 2g). As expected, pulsing with GTP did not modify
the pattern of Ras activation at any of the three stimula-
tion time points chosen for permeabilization. Loading
cells with GppNHp did not affect Ras-GTP levels before
(null Sos activity) and 5 min after EGF stimulation (high
Sos activity) as compared to GTP. However, GppNHp
induced robust accumulation of active Ras at 20 min
EGF, a time at which Ras-GTP levels have vanished in
intact cells (Fig. 1a) or in permeabilized cells loaded with
GTP (Fig. 2g). These observations indicated, firstly, that
Sos is highly active at 20 min post-EGF, driving fast
uptake of GppNHp by Ras, confirming the nucleotide
exchange measurements shown in Fig. 2c and d. Sec-
ondly, the fact that Ras-GppNHp but not Ras-GTP ac-
cumulates at 20 min EGF proved the presence of high
Ras-GAP activity during Ras deactivation. We concluded
that Ras deactivation is enforced by an increase in GAP
activity that counteracts high GEF activity at late time
points of growth factor action.
A negative feedback loop promotes Ras deactivation
Numerous studies have described a feedback loop acting
via the Ras/Raf/MEK/Erk pathway through Sos inhib-
ition to terminate Ras activation [13, 16–18, 43]. Most
investigators postulated a role for Sos-phosphorylation
in the inhibition of Sos activity and Ras deactivation but
this aspect is disputed as others found that Ras activa-
tion kinetics were unaffected by the phosphorylation
state of Sos [19, 20, 22]. Since we did not observe an in-
hibition of Sos during Ras deactivation we investigated
the mode of action of the negative feedback. As reported
previously [13, 15, 18], pharmacological inhibition of
MEK using two distinct inhibitors or siRNA-mediated
combined knockdown of MEK1/MEK2 prolonged Ras-
GTP accumulation (Fig. 3a, Additional file 3: Figure S2).
Operation of the feedback did not require cross-talk
between the three Ras isoforms K-Ras, N-Ras and H-Ras
because it proceeded in engineered MEFs expressing
only K-Ras [49] (Fig. 3b). The feedback was specifically
wired through the Erk pathway as it was not affected by
inhibition of the Ras-effector PI3K (Fig. 3c). Finally,
using trivalent fluorescent affinity probes for Ras-GTP
[50, 51] to visualize Ras activation in life HeLa cells we
ascertained that prolonged Ras activation following
MEK inhibition reflected a uniform cellular response
rather than a conglomerate of Ras activation kinetics
(Fig. 3d).
The feedback mechanism of Ras deactivation involves Erk
and Rsk1/2 and stimulation of a RasGAP activity
To determine the signal path downstream of MEK, we
inhibited Erk and Rsk, two downstream kinases that
reportedly mediate feedback inhibition of the pathway
[16, 17, 26, 29]. Inhibition of Erk (Fig. 4a) or Rsk (Fig. 4b)
exerted a similar prolongation of Ras-GTP formation as
MEK inhibition, albeit somewhat less potently in the
case of Rsk. While assessing the specificity of Rsk inhib-
ition, we noticed that phosphorylation of the Rsk sub-
strate GSK3ß did not decline in cells treated with the
Rsk inhibitor BI-D1870 (Fig. 4b). This was probably
owed to the simultaneously proceeding activation of Akt
(monitored by its phosphorylation on Ser473 in Fig. 4b),
which was further enhanced in cells treated with the Rsk
inhibitor. Akt phosphorylates the same residue on Gsk3ß
as Rsk and both kinases have been shown to contribute
to growth-factor-induced Gsk3ß phosphorylation in vari-
ous cell types [26, 52]. To test more stringently the
specificity of the Rsk inhibitor we also monitored phos-
phorylation of ribosomal protein S6, a target of p70-S6K,
a kinase closely related to Rsk. Phosphorylation of ribo-
somal S6 protein was not affected by BI-D1807 treat-
ment, supporting the specificity of the inhibitor. The
involvement of Rsk in the negative feedback to Ras was
further corroborated by combined RNAi-mediated
knockdown of Rsk1 and Rsk2 (the two Rsk isoforms
expressed in HeLa cells (Fig. 4c)), which produced a
similar extension of Ras activation kinetics (Fig. 4d).
Interestingly, the single knockdown of either Rsk1 or
Rsk2 alone had no effect on Ras deactivation (Fig. 4e),
indicating that the two kinase isoforms may perform re-
dundant roles in feedback control of Ras activity. Along
this line of thinking, the observation that the effect of
Rsk inhibition on Ras inactivation (Fig. 4b and d) was
less pronounced than the one caused by Erk blockade
(Fig. 4a) suggested that Erk played a distinct role in the
feedback deactivation of Ras independent from its role
as upstream activator of Rsk. Interestingly, a similar col-
laboration between Erk and Rsk1/2 has been put forward
before in the context of Sos feedback inhibition [24].
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These findings evidenced that a negative feedback op-
erating via Erk and Rsk1/2 mediates Ras deactivation.
Since we did not observe an ostensible reduction in GEF
activity during the decline of Ras-GTP levels (Fig. 2c, d)
the feedback loop was unlikely to involve a strong
down-regulation of Sos activity as the only mechanism
of Ras deactivation. To test this hypothesis we investi-
gated the consequences of interrupting the feedback on
nucleotide exchange. Inhibition of MEK (Fig. 4f ) or Rsk
(Fig. 4g) restored Ras-GTP formation at 20 min or
higher EGF in a background of unchanged strong nu-
cleotide exchange. This finding provided further support
for the concept that the feedback mechanism of Ras
deactivation involves the activation of a Ras-GAP.
Neurofibromin mediates Ras deactivation
In order to identify the Ras-GAP species involved in Ras
deactivation we performed single knockdowns of RASA1
(Fig. 5a), DAB2IP (Fig. 5b) or neurofibromin (Fig. 5c).
Remarkably, only knockdown of neurofibromin pro-
longed Ras-GTP accumulation. The same effect was ob-
served in cells with stable shRNA-mediated knockdown
of neurofibromin (Fig. 5d). Neurofibromin knockdown
increased Ras-GTP accumulation 20 min post-EGF
without affecting the rate of nucleotide uptake by Ras
(Fig. 5e). This pattern was the same as obtained by
pharmacological interruption of the feedback (Fig. 4a, b),
corroborating that neurofibromin mediates the deactiva-
tion of Ras. Of note, we did not observe growth factor-
Fig. 3 Inhibition of the MEK/Erk/Rsk pathway prolongs Ras activation. a Resting HeLa or MEF cells were left untreated or treated with the MEK
inhibitor U0126 (10 μM), followed by EGF stimulation and analysis of Ras and Erk activity. b Same experiment as in A performed in H-Ras-/-,
N-Ras-/-, K-Raslox/lox MEFs expressing only K-Ras. c HeLa cells pretreated with the MEK inhibitor U0126 or the PI3K inhibitor Wortmannin (30 min,100
nM) were challenged with EGF and subjected to a biochemical Ras activation assay. d HeLa cells expressing the trivalent affinity probe for Ras-GTP
E3-R3(A/D) (see experimental section and Ref.[51]) were treated with U0126 or left untreated prior to stimulation with 10 ng/ml EGF.
The time-dependent re-distribution of E3-R3(A/D) was imaged alive by confocal laser scanning microscopy. Probe relocation to the plasma
membrane (marked by arrowheads) illustrates Ras activation. Over 30 cells monitored in 3-5 individual experiments responded with the
same redistribution kinetics
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Fig. 4 Rsk1 and Rsk2 mediate the feedback deactivation of Ras. a HeLa cells treated or not with the Erk inhibitor FR108204 were challenged with
EGF for the indicated periods of time and subjected to a Ras-GTP pulldown assay. The phosphorylation/activation state of the indicated proteins
was determined using phophosite-specific antibodies. Phospho-MAPK Substrates (PXS*P or S*PXR/K): Ab recognizing the phosphorylated
Erk consensus motif. Asterisk denotes an unspecific band. b Same experiment in cells pre-treated with the pan-Rsk inhibitor BI-D1870. The activation
status of Erk was monitored using phospho-site specific antibodies against Erk. Acute inhibition of Rsk with BI-D1870 did not affect Rsk protein stability
as illustrated by the immunodetection of total Rsk1/Rsk2/Rsk3. c Real-time PCR analysis of Rsk isoform expression in HeLa cells. d Rsk1 and Rsk2
were simultaneously silenced via siRNA in HeLa cells followed by stimulation with EGF and biochemical analysis of Ras activation. e Biochemical
determination of Ras-GTP levels and Erk activity in HeLa cells previously subjected to single or combined siRNA-mediated knockdown of Rsk1
and Rsk2. Immunodetection of p70S6K/p85S6K was performed as a control of specificity of the siRNA-mediated knockdown of Rsk1/2. Asterisk
denotes an unspecific band. f Feedback deactivation of Ras is mediated via GAP up-regulation. HeLa cells were pretreated with U0126 where
indicated, challenged with 10 ng/ml EGF and subjected to analysis of Ras nucleotide exchange. g Same experiment as in (a) performed in cells
treated with the pan-Rsk inhibitor BI-D1870
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dependent changes in neurofibromin levels in any of the
cell types studied here (HeLa, HEK293 or MEF cells),
which indicated that regulated neurofibromin ubiquiti-
nation/degradation as a mechanisms of Ras activity con-
trol does not occur in these cells [35, 36]. Taken
together, our findings describe a precise role of neurofi-
bromin in the control of Ras activity by growth factors
and illustrate how, by engaging Ras-GAP activity,
mitogen-challenged cells ensure a timely termination of
the Ras signal irrespectively of the reigning rate of nu-
cleotide exchange.
In 2004 Markevich et al. predicted on purely theoret-
ical grounds that Sos downregulation was insufficient to
effectively deactivate Ras [42] but many studies have
continued invoking it as the basis of negative feedbacks
in their models. Our finding that GEF activity does not
decay significantly during Ras deactivation suggests that
feedback inhibition of Sos is not the major mechanism
Fig. 5 Feedback-mediated stimulation of neurofibromin mediates Ras deactivation. a EGF-induced Ras activation in HeLa cells subjected to previous
siRNA-mediated silencing of RASA1. siRNA-transfected cells were additionally treated with the MEK inhibitor U0126 in order to ascertain that siRNA
transfections did not distort the feedback mechanism of Ras deactivation. b Same experiment as in (a) in DAB2IP-silenced HeLa cells.
c Same experiment as in (b) performed in neurofibromin-silenced HeLa cells. d Time course of EGF-driven Ras activation in HEK293T cells
and a derivative line with stable shRNA-mediated knockdown of neurofibromin. e HeLa cells subjected to siRNA mediated silencing of
neurofibromin were challenged with EGF. Cells were permeabilized prior to or 5 and 20 min after EGF stimulation and processed for the
analysis of nucleotide exchange on Ras
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of Ras deactivation, at least in the cell types studied here.
Moreover, that model can only explain transient Ras
activation by assuming high basal GAP activity (Fig. 1e),
which was also not corroborated by our findings (Fig. 1f ).
Our data also provide evidence that feedback phosphor-
ylation of Sos is not accompanied by a measurable
decrease in nucleotide exchange and may therefore be
more relevant for other signaling actions of Sos, perhaps
related to the control of Rac and the actin cytoskeleton
[53]. Interestingly, other investigators reached the same
conclusion before by other means [54].
Figure 6a and b show a mechanistic and a revised min-
imal mathematical model, respectively, that incorporate
all present findings and can explain transient Ras activa-
tion by the sequential engagement of a GEF (Sos) and
feedback stimulation of a GAP (neurofibromin) without
the need to invoke other regulatory mechanisms. It is
important to note that this model rationalizes all experi-
mental findings reported herein for HeLa and MEF cells
but alternative mechanisms involving other GEFs and/or
GAPs may apply in other systems like neuronal or
hematopoetic cells, which express a broader range of
RasGEF and RasGAP species [55].
Extensive work suggests that the life-time of Ras acti-
vation has dramatic consequences on cell fate. In most
investigated settings prolonged activation of the Ras/Erk
pathway prohibits proliferation and shifts the balance to
differentiation [1, 2, 56]. Our findings imply that loss of
neurofibromin is likely to prolong rather than enhance
the amplitude of Ras signaling, potentially providing a
signal that is not compatible with excess proliferation,
which could explain in part the absence of neoplastic
growth in many tissues in neurofibromatosis. Interest-
ingly, Schwann cells, the cell type most affected in
neurofibromatosis, represent an exception to that rule,
as enforced Ras/Erk signaling induces dedifferentiation
of that cell type [57]. Our findings raise the possibility
that aberrant prolongation of Ras-signaling owing to the
loss of neurofibromin could drive dedifferentiation enab-
ling aberrant growth in neurofibroma development.
Inactivating mutations in Rsk2 are causative of the
Coffin-Lowry syndrome [58]. The involvement of both
Rsk2 and neurofibromin in feedback deactivation of Ras
suggests that both syndromes could share molecular
mechanisms. In support of this notion, there are case
reports of patients initially diagnosed with Noonan syn-
drome (one of several so-called rasopathies characterized
by modest hyperactivation of the Ras/Erk pathway [59])
whose diagnosis was later on changed on the basis of re-
sequencing to either NF1 or Coffin-Lowry [60]. Our
finding of a negative feedback loop for Ras deactivation
involving neurofibromin and Rsk2 rationalizes how in-
activating mutations in Rsk2, a kinase with assumedly
pro-mitogenic features, can give rise to a rasopathy-like
phenotype.
Conclusions
This study shows that transient Ras activation in re-
sponse to growth factors is ensured by the sequential
stimulation of Sos and the ensuing activation of the
Fig. 6 Model of Ras deactivation mediated by the feedback-dependent activation of neurofibromin. a Schematic cartoon of the mechanism of
Ras activation/deactivation. The scheme depicts the previously reported Erk and/or Rsk-dependent feedback inhibition of GEF (Sos) activation and
the feedback stimulation of neurofibromin reported herein. The dotted line linking Erk to neurofbromin symbolizes the presumptive Rsk-independent
feedback loop emanating from Erk. See text for details. b Minimal mathematical model describing Ras activation/deactivation mediated by a positive
feedback stimulation of Ras-GAP. R-GEF: receptor-GEF complex. See experimental section for details
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tumor suppressor Ras-GAP protein neurofibromin in
the context of a feedback mechanism that involves also
Rsk1/2. Hence, transient Ras signal termination does not
result solely from feedback inhibition of Sos-driven
nucleotide exchange but involves additionally feedback
stimulation of neurofibromin RasGAP activity. This model
of Ras activation represents a new paradigm and assigns
for the first a time a precise role to neurofibromin in
growth-factor-dependent control of Ras activity.
Methods
Cell culture and treatments/stimulations
Cervical cancer (HeLa) cells, Mouse embryonic fibro-
blasts (MEF), H-Ras-/-, N-Ras-/-, K-Raslox/lox MEFs
(kindly provided by Mariano Barbacid, Madrid, Spain)
and Human Embryonic Kidney 293 (HEK293T) cells
were cultured at 37 °C and 5 % CO2 atmosphere in
DMEM (Dulbecco’s modified Eagle’s medium) supple-
mented with 10 % (v/v) fetal calf serum. Inhibitor treat-
ments: all inhibitors were applied for 30 min at the
following concentrations: U0126 (10 μM), FR108204
(50 μM) BI-D1870 (10 μM), Wortmannin (100 nM).
EGF was added at a final concentration of 10 ng/ml.
Reagents
Streptolysin O was purchased from AaltoBio Reagents
(Dublin, Ireland). Glutathione–Sepharose and all nu-
cleotides were from JenaBioscience (Jena, Germany).
[α-32P]GTP (370 MBq/ml; no. SCP-208) was from
Hartmann Analytic (Braunschweig, Germany). Gamma-
Bind–Sepharose was purchased from Amersham Biosci-
ences (Freiburg, Germany). U0126 and BI-D1870 were
purchased from Enzo Life Science (Lörrach, Germany).
The Erk1 and Erk2 selective inhibitor FR108204 [61] was
from Sigma–Aldrich (Munich, Germany). All inhibitors
were stored at -20 C in DMSO. Epithelial growth factor
(EGF) were purchased from Life Technologies (Darmstadt,
Germany). All siRNAs were ON-TARGETplus SMART-
pools purchased from Dharmacon (Dharmacon RNAi
Technologies, Thermo Fisher Scientific, Lafayette,
USA): Human RASA1 (5921) (L-005276-00-0005),
Human NF1 (L-003916-00-0005), Human DAB2IP (L-
008249-01-0005), Human RPS6KA3 (L-003026-00-0005),
Human RPS6KA1 (L-003025-00-0005), Map2k1 (L-
003571-00-0005), Map2k2 (L-003573-00-0005). Saint-Red
transfection reagent was from Synvolux Therapeutics
(Groningen, Netherlands).
Antibodies
Antibodies were obtained from the following sources:
SOS1 (clone 25/SOS1), p120RasGAP (clone 13/RAS-
GAP), MEK1 (no. 610121), MEK2 (no. 610235) were
from BD Transduction Laboratories; K-Ras F234 (sc-30),
N-Ras F155 (sc-31), pan-Ras C-4 (sc-166691), p-ERK1/
2(Y204) (sc-101761), and Neurofibromin (sc-67) from
Santa Cruz Biotechnology (Heidelberg, Germany);
Phospho-MAPK/CDK Substrates (PXS*P or S*PXR/K)
(34B2) (no. 2325), p44/42 MAPK (ERK1/2) (no. 4695),
Akt (no. 9272), p-Akt(S473) (no. 4060), EGFR (no.
4267), p-EGFR (Y1068) (no. 2236), Phospho-p90RSK
(Ser380) (no. 9341), RSK1/RSK2/RSK3 (32D7) (no.
9355), p-GSK-3β (Ser9) (D85E12) (no. 5558); GSK-3β
(27C10) (no. 9315), Phospho-S6 Ribosomal Protein
(Ser235/236) (no. 2211), S6 Ribosomal Protein (5G10)
(no .2217), p70 S6 Kinase (49D7) (no. 2708) were from
Cell Signaling Technology (Danvers, USA). Anti-
DAB2IP (ab87811) was from Abcam (Cambridge, UK).
Y13-259 rat monoclonal anti-Ras IP-antibody was puri-
fied from hybridoma supernatant (A.T.C.C., Manassas,
U.S.A.).
RNA isolation, cDNA synthesis and quantitative real-time
PCR analysis
Total RNA isolation and purification was performed using
an RNA isolation kit from Macherey-Nagel (Düren,
Germany) according to the manufacturer’s protocol.
cDNA synthesis was performed using First Strand cDNA
Synthesis Kit (Thermo Scientific, Schwerte, Germany)
with 50 ng/μl of total RNA per sample and Oligo-dT-
based priming. QRT-PCR was performed using Maxima
SYBR Green/ROX qPCR Master Mix (2X) (Thermo
Scientific, Schwerte, Germany) using primers for all four
RSK isoforms reported in [62]. Relative transcript levels
were determined by calculating 2deltaCt values, using
GAPDH expression levels for normalization.
Plasmids and transient transfection
GFP-neurofibromin (type 1 isoform) was cloned in
pCDH-EF1a-EGFP-C2-IRES-Puro, a customized vector
based on the parental vector pCDH-EF1-EGFP-C2-
IRES-Puro from System Biosciences, with expression
driven by the EF1a promoter. Cloning details will be
presented elsewhere. An expression construct for HA-
tagged RASA1 [63] was kindly provided by Christian
Widmann, University of Lausanne, Switzerland. Neu-
rofibromin was stably knocked down in HEK293T
cells via lentiviral transduction of a shRNA construct.
The targeting sequence GCTGGCAGTTTCAAACG
TAA embedded in a miRNA scaffold was cloned into
pLV-H1-SGIPZ, a customized lentiviral vector based
on pGIPZ vector (Open Biosystems). The resulting pLV-
H1-SGIPZ-NF1sh1miR, together with psPAX2 (Addgene
#12260) and pMD2.G (Addgene #12259), were transiently
transfected into 293 T cells to produce lentiviral particles.
48 h post-transfection, the supernatant was harvested,
filtrated through a 0.45 μM filter and used to infect 293 T
cells. 48 h post-infection, puromycin selection was started
to obtain the stable cell line. Transient transfections
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were performed using Polyethylenimine as described
[64]. ON-TARGETplus siRNA-SMARTpool™ siRNAs
were transfected using the Saint-Red transfection
reagent from Synvolux Therapeutics exactly as described
before [65].
Ras-GTP pull-down assay
Cells seeded in 6 well plates were deprived of serum
overnight, challenged or treated as appropriate and lyzed
in 0.5 ml ice-cold lysis solution [50 mM Tris pH 7.5,
150 mM NaCl, 1 mM EGTA, 5 mM MgCl2, 1 % NP40
(Nonidet-P40)] supplemented with protease and phos-
phatase inhibitors, 100 μM GDP and 25 μg/ml soluble
recombinant GST-RBD (Ras binding domain of Raf-1;
previously produced in E. coli by standard procedures).
GDP and GST-RBD were included in the lysis buffer to
quench post-lytic GTP-loading and GAP-dependent
Ras-bound GTP hydrolysis, respectively. Cell material
was scraped off and lysates were cleared by centrifuga-
tion. GST-Raf-1-RBD/Ras-GTP complexes were col-
lected on glutathione-sepharose (30 min at 4 °C on a
rotating wheel), washed once with 750 μl lysis buffer
lacking GDP and GST–Raf-1-RBD and processed for
Western Blotting.
Permeabilization and Nucleotide exchange assay
Cell permeabilization was performed essentially as de-
scribed previously [66]. Serum-starved HeLa or MEF
cells seeded in 6-well plates were treated/stimulated as
appropriate and reactions were started by replacing the
medium with 0.6 ml/well pre-warmed permeabilization
solution (50 mM Hepes, pH 7.5, 107 mM potassium glu-
tamate, 23 mM NaCl, 3 mM MgCl2, 0.1 mM CaCl2,
1 mM EGTA, 2 mM Dithiothreitol, 1 mM ATP) supple-
mented with freshly thawed 15 unit/ml SLO and 9 MBq
[α-32P]GTP. For treated cells, this solution was supple-
mented with the relevant drug. Kinetics were started at
this point and reactions were quenched by aspirating the
solution and lysing cells in 1 ml/well ice-cold lysis buffer
(50 mM Hepes, pH 7.5, 100 mM NaCl, 10 mM MgCl2,
1 % NP40, 100 μM GDP, 100 μM GTP and protease
inhibitors) supplemented with 2,5 μg/ml Y13-259 Ras-
antibody for IP. Cells were scraped off and extracts were
placed on ice. Lysates were cleared by centrifugation and
supernatants were made up to 500 mM NaCl, 0.5 %-
sodium deoxycholate and 0.05 % SDS. Immunocom-
plexes were collected on GammaBind–Sepharose by
45 min incubation at 4 °C under rotation. After six
rounds of washing with 1 ml of ice-cold washing solu-
tion (50 mM Hepes, pH 7.5, 500 mM NaCl, 5 mM
MgCl2, 0.1 % Triton X-100 and 0.005 % SDS), immuno-
precipitates were subjected to Cerenkov counting. Ras
nucleotides were eluted from the same samples and ana-
lyzed by Thin Layer Chromatography [66]. GDP and
GTP spots were densitometrically quantified using Multi
Gauge software.
GEO search
The cervical carcinoma HeLa cells gene expression data-
sets reporting on the transcriptome of EGF-stimulated
HeLa cells [44] were identified in GEO dataset ID
GSE6783 with the platform ID GPL96.
Confocal microscopy
Live-cell imaging was performed on a Zeiss LSM 510 axio-
vert confocal microscope equipped with a thermostated
stage chamber (IBIDI, München, Germany) as previously
described [67]. Briefly, confocal images (optical slice of ≤
1 μm) were acquired using a 63x water immersion object-
ive lens. EGFP was excited with the Argon 488 nm line
and emitted fluorescence was collected with a 505–550 nm
band-pass filter. All images of a series were exported as
TIF files and subjected to the same processing routine
using Zeiss ZEN 2008 Light Edition software.
Mathematical modeling
A toy ODE model was built for two alternative network
structures that represent regulation through GEF only
(Fig. 1d), or GAP only (Fig. 6b). Both models share a
common core to which we add a feedback loop that
either decreases GEF activity or increases GAP activity.
In the model Ras cycles between GDP and GTP bound
states with Michaelis-Menten kinetics, the balance of
which depends on the GEF/GAP ratio. To simulate EGF
stimulation, receptor recruits GEF to form receptor-GEF
complex (R-GEF) increasing the rate of Ras-GTP forma-
tion. Downstream signaling from Ras-GTP enforces the
feedback after a small time delay to account for the
MAPK cascade. In the GEF-only model, feedback cata-
lyzes the separation of R-GEF complexes into free recep-
tors and inactive GEF. In the GAP-only model, feedback
catalyzes the activation of GAP molecules. The parame-
ters of each model were adjusted to allow Ras-GTP
dynamics to match Fig. 1a. All simulations were per-
formed with the SimBiology toolbox within MATLAB
R2013b. Details of the model are described in the sup-
plementary information (Additional file 2: Table S1).
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional file(s).
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Additional file 1: EGF-induced electrophoretic mobility shift of Sos
is sensitive to MEK (10 μM UO126) and Erk (50 μM FR180204) but
not Rsk (10 μM BI-D1870) or PI3K (100nM Wortmannin) inhibition.
HeLa cells pre-treated with the indicated inhibitors or subjected to siRNA-
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mediated knockdown of neurofibromin (siNF1) were deprived of serum
overnight and challenged 30 min with EGF. Lysates were processed for
immunodetection of Sos, Rsk1/2/3 and Erk. (PDF 598 kb)
Additional file 2: Details of the “GEF only” and “GAP only” model.
(PDF 174 kb)
Additional file 3: Combined knockdown of MEK1 and MEK2 causes
prolonged Ras activation. EGF-induced Ras activation was assessed
biochemically after single or combined siRNA-mediated knockdown
of MEK1 and MEK2. RBD designates the coomassie-stained Ras binding
domain used to collect Ras-GTP from cell lysates. Note that single knockdown
of MEK1 or MEK2 leads to opposite effects on Ras-GTP levels, pointing
to different roles of both kinases in Ras activity control. The same
effect was previously reported by Kamioka et al. [13]. (PDF 28364 kb)
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